ScholarIQanswers from OpenAlex
International Journal of Nephrology and Renovascular Disease
JournalCitation impact & published research
International Journal of Nephrology and Renovascular Disease is a journal indexed in ScholarIQ from OpenAlex.
How many works does International Journal of Nephrology and Renovascular Disease have?
ScholarIQindexed works
International Journal of Nephrology and Renovascular Disease has 554 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does International Journal of Nephrology and Renovascular Disease have?
ScholarIQcitation count
International Journal of Nephrology and Renovascular Disease has 12,594 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of International Journal of Nephrology and Renovascular Disease?
ScholarIQh-index
International Journal of Nephrology and Renovascular Disease has an h-index of 52 in OpenAlex.
What is the article processing charge of International Journal of Nephrology and Renovascular Disease?
ScholarIQarticle processing charge
International Journal of Nephrology and Renovascular Disease lists an article processing charge of 2,320 USD in OpenAlex.
What is the OpenAlex record for International Journal of Nephrology and Renovascular Disease?
ScholarIQopenalex
The OpenAlex for International Journal of Nephrology and Renovascular Disease is on the source record.
What are the most-cited papers on International Journal of Nephrology and Renovascular Disease?
ScholarIQmost cited works
Vascular access for hemodialysis: current perspectives
Domenico Santoro, Filippo Benedetto, Placido Mondello, Francesco Spinelli, Carlo Alberto Ricciardi, Valeria Cernaro, Michele Buemi, Narayana Pipitò, David Barillà
Rodent models of diabetic nephropathy: their utility and limitations
Munehiro Kitada, Yoshio Ogura, Daisuke Koya
Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations
Laia Sans-Atxer, Dominique Joly
<p>Optimal management of atypical hemolytic uremic disease: challenges and solutions</p>
Rupesh Raina, Manpreet Kaur Grewal, Yeshwanter Radhakrishnan, Vineeth Tatineni, Meredith DeCoy, Linda Burke, Arvind Bagga
Is the light at the end of the tunnel nigh? A review of ADPKD focusing on the burden of disease and tolvaptan as a new treatment
Rashid A. Barnawi, Rahaf Zyad Attar, Sultan Alfaer, Osama Safdar